Telix Pharmaceuticals (TLX) Accounts Payables (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Accounts Payables for 3 consecutive years, with $150.3 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 64.3% to $150.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $150.3 million through Dec 2025, up 64.3% year-over-year, with the annual reading at $150.3 million for FY2025, 73.23% up from the prior year.
  • Accounts Payables for Q4 2025 was $150.3 million at Telix Pharmaceuticals, up from $91.5 million in the prior quarter.
  • The five-year high for Accounts Payables was $150.3 million in Q4 2025, with the low at $21.4 million in Q4 2023.
  • Average Accounts Payables over 3 years is $87.7 million, with a median of $91.5 million recorded in 2024.
  • The sharpest move saw Accounts Payables skyrocketed 328.07% in 2024, then surged 64.3% in 2025.
  • Over 3 years, Accounts Payables stood at $21.4 million in 2023, then surged by 328.07% to $91.5 million in 2024, then skyrocketed by 64.3% to $150.3 million in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $150.3 million, $91.5 million, and $21.4 million for Q4 2025, Q4 2024, and Q4 2023 respectively.